Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity.

Autor: Cabral-Marques O; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil. otavio.cmarques@usp.br.; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, Brazil. otavio.cmarques@usp.br.; Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Sao Paulo, Brazil. otavio.cmarques@usp.br., Halpert G; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.; Saint Petersburg State University, Saint-Petersburg, Russia., Schimke LF; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil., Ostrinski Y; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.; Saint Petersburg State University, Saint-Petersburg, Russia.; Ariel University, Ariel, Israel., Vojdani A; Department of Immunology, Immunosciences Laboratory, Inc., Los Angeles, CA, United States.; Cyrex Laboratories, LLC 2602S. 24th St., Phoenix, AZ, 85034, USA., Baiocchi GC; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil., Freire PP; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil., Filgueiras IS; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil., Zyskind I; Department of Pediatrics, NYU Langone Medical Center, New York, NY, USA.; Maimonides Medical Center, Brooklyn, NY, USA., Lattin MT; Department of Biology, Yeshiva University, Manhatten, NY, USA., Tran F; Department of Internal Medicine I, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany., Schreiber S; Department of Internal Medicine I, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany., Marques AHC; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil., Plaça DR; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, Brazil., Fonseca DLM; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, Brazil., Humrich JY; Department of Rheumatology, University Medical Center Schleswig-Holstein Campus Lübeck, Lübeck, Germany., Müller A; Department of Rheumatology, University Medical Center Schleswig-Holstein Campus Lübeck, Lübeck, Germany., Giil LM; Department of Internal Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway., Graßhoff H; Department of Rheumatology, University Medical Center Schleswig-Holstein Campus Lübeck, Lübeck, Germany., Schumann A; Department of Rheumatology, University Medical Center Schleswig-Holstein Campus Lübeck, Lübeck, Germany., Hackel A; Department of Rheumatology, University Medical Center Schleswig-Holstein Campus Lübeck, Lübeck, Germany., Junker J; CellTrend Gesellschaft mit beschränkter Haftung (GmbH), Luckenwalde, Germany., Meyer C; CellTrend Gesellschaft mit beschränkter Haftung (GmbH), Luckenwalde, Germany., Ochs HD; Department of Pediatrics, University of Washington School of Medicine, and Seattle Children's Research Institute, Seattle, WA, USA., Lavi YB; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel., Scheibenbogen C; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Dechend R; Experimental and Clinical Research Center, a collaboration of Max Delbruck Center for Molecular Medicine and Charité Universitätsmedizin, and HELIOS Clinic, Department of Cardiology and Nephrology, Berlin, 13125, Germany., Jurisica I; Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, UHN; Data Science Discovery Centre, Krembil Research Institute, UHN, Departments of Medical Biophysics and Computer Science, University of Toronto, Toronto, Canada.; Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia., Schulze-Forster K; CellTrend Gesellschaft mit beschränkter Haftung (GmbH), Luckenwalde, Germany., Silverberg JI; School of Medicine and Health Sciences, George Washington University, Washington, DC, USA., Amital H; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel., Zimmerman J; Maimonides Medical Center, Brooklyn, NY, USA., Heidecke H; CellTrend Gesellschaft mit beschränkter Haftung (GmbH), Luckenwalde, Germany., Rosenberg AZ; Department of Pathology, Johns Hopkins University, Baltimore, MD, USA., Riemekasten G; Department of Rheumatology, University Medical Center Schleswig-Holstein Campus Lübeck, Lübeck, Germany. gabriela.riemekasten@uksh.de., Shoenfeld Y; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel. shoenfel@post.tau.ac.il.; Saint Petersburg State University, Saint-Petersburg, Russia. shoenfel@post.tau.ac.il.; Ariel University, Ariel, Israel. shoenfel@post.tau.ac.il.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2022 Mar 09; Vol. 13 (1), pp. 1220. Date of Electronic Publication: 2022 Mar 09.
DOI: 10.1038/s41467-022-28905-5
Abstrakt: COVID-19 shares the feature of autoantibody production with systemic autoimmune diseases. In order to understand the role of these immune globulins in the pathogenesis of the disease, it is important to explore the autoantibody spectra. Here we show, by a cross-sectional study of 246 individuals, that autoantibodies targeting G protein-coupled receptors (GPCR) and RAS-related molecules associate with the clinical severity of COVID-19. Patients with moderate and severe disease are characterized by higher autoantibody levels than healthy controls and those with mild COVID-19 disease. Among the anti-GPCR autoantibodies, machine learning classification identifies the chemokine receptor CXCR3 and the RAS-related molecule AGTR1 as targets for antibodies with the strongest association to disease severity. Besides antibody levels, autoantibody network signatures are also changing in patients with intermediate or high disease severity. Although our current and previous studies identify anti-GPCR antibodies as natural components of human biology, their production is deregulated in COVID-19 and their level and pattern alterations might predict COVID-19 disease severity.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: